PubMed
Cagrilintide, a long-acting amylin analogue, for the treatment of obesity
Lau et al., 2022
GLP-1 & MetabolicPhase 3 ProgramA
Cagrilintide
AM833
Long-acting amylin analog studied for obesity and metabolic disease.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 5
- Research grade
- A
- Experience
- 99
- Activity
- 86
Overall check-ins
Trackers & reports
Overview
About Cagrilintide
Long-acting amylin analog studied for obesity and metabolic disease.
- Category
- GLP-1 & Metabolic
- Regulatory status
- Phase 3 Program
- Also known as
- AM833
- Self-reports
- 29
Community
What 29 users report
29 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 98% · Mixed 2% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
139
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Nausea
1
Digestive upset
1
Injection site irritation
1
Self-reported dose per injection
Median bucket: 2+ mg · Most common: 2+ mg
Reports span 0 to ≥ 2 mg (open-ended top bucket)
0–0.025 mg
41
0.2–0.4 mg
9
0.4–0.6 mg
2
0.6–1 mg
3
1–2 mg
1
2+ mg
83
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 87% said they felt similar to their last entry, 13% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 142 days · Based on 23 repeat reporters
Research
Cited research (4)
Source
ClinicalTrials.gov
Cagrilintide obesity studies on ClinicalTrials.gov
ClinicalTrials.gov, 2024
PubMed
Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity
D'Ascanio et al., 2024
PubMed
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
Garvey et al., 2025
Tools
Explore more
Explore
More ways to learn about Cagrilintide from observational PeptIQ data.
Compare with
Related peptides
Help
Frequently asked
What do PeptIQ users report about Cagrilintide?
This page summarizes 29 anonymized self-reports from PeptIQ users who track Cagrilintide, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for Cagrilintide?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for Cagrilintide?
4 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is Cagrilintide safe to use?
This wiki does not assess safety or recommend use. Cagrilintide is listed as Phase 3 Program. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of Cagrilintide?
Research, primarily in animal models, suggests Cagrilintide may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceWhat is the legal status of Cagrilintide?
Cagrilintide is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified Cagrilintide as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceWhat are the known or theoretical side effects and risks of Cagrilintide?
The safety and effectiveness of Cagrilintide have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhat is the current state of research on Cagrilintide?
While there are over 200 published studies on Cagrilintide, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source